Intercept Pharmaceuticals (NAS:ICPT) Debt-to-Equity

: 4.96 (As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

Intercept Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $109.7 Mil. Intercept Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $223.4 Mil. Intercept Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $67.2 Mil. Intercept Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2023 was 4.96.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intercept Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ICPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -15.95 Med: 0.95 Max: 21.71
Current: 4.96

During the past 13 years, the highest Debt-to-Equity Ratio of Intercept Pharmaceuticals was 21.71. The lowest was -15.95. And the median was 0.95.

ICPT's Debt-to-Equity is ranked worse than
98.09% of 1097 companies
in the Biotechnology industry
Industry Median: 0.14 vs ICPT: 4.96

Intercept Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Intercept Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

19.41

10.62

-3.45

-2.95

3.57

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity																-1.95	-1.93	3.09	3.57	4.96

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Intercept Pharmaceuticals Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Debt-to-Equity falls in comparison to its industry or sector. The grey bar indicates the Debt-to-Equity's extreme value range as defined by GuruFocus.

Intercept Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intercept Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(109.569	+	223.104)	/	93.077
	=	3.57

Intercept Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(109.688	+	223.352)	/	67.185
	=	4.96

Intercept Pharmaceuticals (NAS:ICPT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Intercept Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451